New combo therapy shows promise for kids with rare lymphoma

NCT ID NCT01516567

Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of chemotherapy drugs (etoposide, doxorubicin, vincristine, cyclophosphamide) plus the targeted drug rituximab in 47 children and teens with primary mediastinal large B-cell lymphoma. The goal was to see how well the regimen prevented the cancer from coming back. Researchers also tracked side effects during and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DA-EPOCH-Rituximab (a combination of chemotherapy drugs etoposide, doxorubicin, vincristine, cyclophosphamide, and the targeted antibody rituximab)
What this could lead to: If successful, this could point toward an effective chemotherapy regimen for children with this rare lymphoma, potentially improving survival rates.
What could go wrong: This is a small, single-arm phase 2 trial with only 47 participants, so results may not apply broadly. Chemotherapy carries risks like infection, heart damage, and long-term immune effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

2nd Dept. of Pediatrics Semmelweis Univ.

Budapest, 1094, Hungary
Associazione Italiana di Ematologia ed Oncologia Pediatrica

Padova, 35128, Italy
Children Oncology Group Operations centres

Monrovia, Canada
Emma Children's Hospital

Amsterdam, 1105 AZ, Netherlands
Gustave Roussy

Villejuif, 94805, France
Rectorat of Medical University

Wroclaw, Poland
Sociedad Española de Hematología y Oncología Pediátricas

Valencia, 46010, Spain
University Hospitals Leuven

Leuven, 3000, Belgium
University of Birmingham

Birmingham, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.